Citations 2
Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Pinto, A. A., Bisneto, J. C. Villasboas, Sanz, R. García, García, Carlos Grande, Smith, Stephen D. , Wallace, D. S., Merryman, R., Marolleau, Jean Pierre, Chêne, Laurent , Fagerberg, Jan, Friedberg, Jonathan W. , Ansel, Sonam , Armand, Philippe , Pinto, A., Bosch, Francesc , Bisneto, J. C. Villasboas, Sanz, R. García, Arcaini, Luca , Marolleau, Jean‐Pierre, Filippi, Rosaria De , Bonny, Christophe , Ansel, S., Zinzani, Pier Luigi
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582
P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
Zinzani, P. L., Ansell, S. M., Bosch, F., Friedberg, Jonathan W. , Marolleau, Jean Pierre, Arcaini, L., Gopal, A. K., Grande, C., Merryman, R., Pinto, A., Smith, S. D., Wallace, D., Fagerberg, J., Magalhaes, J. G., Armand, P., Zinzani, Pier Luigi , Ansell, Stephen M., García‐Sánz, Ramón , Gopal, A., Pinto, A., Villasboas, José C. , Fagerberg, J., Magalhaes, J. Gamelas
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1005-1006